Celiac disease (CD) is a genetically determined autoimmune enteropathy, induced by gluten ingestion. To date, different prevalences of CD in children with epilepsy have been reported. The aim of this study was to determine CD prevalence in our patients with epilepsy, using anti-tissue transglutaminase (tTG) antibodies as a screening test. One hundred twenty-five children (72 girls, 53 boys; age range: 2-18 years, mean age: 10.51 +/- 3.53) with idiopathic epilepsy from South East Serbia were tested for immunoglobulin (IgA) tTG antibodies. All positive patients were offered endoscopic small bowel biopsy. Biopsies were examined histopathologically in order to confirm the CD diagnosis. The control group consisted of 150 healthy children. Three patients with epilepsy were positive for IgA tTG antibodies. In all of them, small bowel biopsy was performed, and only one was proven to have CD by histopathology (Marsh IIIa grade). The prevalence of biopsy-proven CD in children with epilepsy was not significantly higher in the study group compared to controls (0.8% vs.0.6%, p > 0.05). The results of this study indicate that children with idiopathic epilepsy from our region should not be routinely tested for CD.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A randomized, double-blind, placebo-controlled, multiple dose, parallel study to investigate the effects of a cathepsin S inhibitor in celiac disease.
Clin Transl Sci
January 2025
F. Hoffmann-La Roche, Basel, Switzerland.
Celiac disease is a chronic, immune-mediated enteropathy with symptoms triggered by exposure to dietary gluten in genetically predisposed individuals. The only available management option is lifelong adherence to a gluten-free diet. This randomized, double-blind, placebo-controlled, parallel-group, single-center study tested the effects of the cathepsin S inhibitor RO5459072 on the immune response to a 13-day gluten challenge in 19 participants with celiac disease (ClinicalTrials.
View Article and Find Full Text PDFA machine learning tool for early identification of celiac disease autoimmunity.
Sci Rep
December 2024
Kahn Sagol Maccabi Research & Innovation Center, Maccabi Healthcare Services, Tel Aviv, Israel.
Identifying which patients should undergo serologic screening for celiac disease (CD) may help diagnose patients who otherwise often experience diagnostic delays or remain undiagnosed. Using anonymized outpatient data from the electronic medical records of Maccabi Healthcare Services, we developed and evaluated five machine learning models to classify patients as at-risk for CD autoimmunity prior to first documented diagnosis or positive serum tissue transglutaminase (tTG-IgA). A train set of highly seropositive (tTG-IgA > 10X ULN) cases (n = 677) with likely CD and controls (n = 176,293) with no evidence of CD autoimmunity was used for model development.
View Article and Find Full Text PDFPrevalence of celiac disease-specific antibodies and their association with clinical status and environmental factors.
Heliyon
December 2024
Grupo de Investigaciones Básicas y Aplicadas en Inmunología y Bioactivos (GIBAIB), Instituto de Ecología y Desarrollo Sustentable (INEDES), (Universidad Nacional de Luján - CONICET), Luján, Buenos Aires, Argentina.
Background And Aims: Celiac disease (CeD) affects 1-2% of the world's population. The aim of this study was to relate the incidence of CeD-related serological markers to symptoms, pathologies, and environmental exposure to wheat flour, given the number of flour mills present in the region.
Materials & Methods: Serum samples were collected from 537 inhabitants from a rural city.
Modified FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: a randomized phase II DEEPER trial.
Nat Commun
November 2024
Department of Clinical Oncology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
The clinical significance of FOLFOXIRI (5-FU, leucovorin, oxaliplatin, and irinotecan) plus anti-EGFR monoclonal antibody using cetuximab for metastatic colorectal cancer (mCRC) remains controversial. We report results from a randomized phase 2 DEEPER trial (UMIN000018217, jRCTs061180022) to test the superiority of modified (m)-FOLFOXIRI plus weekly cetuximab over bevacizumab in patients with RAS wild-type (wt) mCRC. Primary endpoint was depth of response (DpR).
View Article and Find Full Text PDFPrevalence of celiac disease in patients with type 1 diabetes mellitus: a single-center cross-sectional cohort study.
J Clin Biochem Nutr
November 2024
Department of Diabetes and Endocrinology, Hyogo Prefectural Harima-Himeji General Medical Center, 3-264, Kamiya-cho, Himeji-shi, Hyogo 670-8560, Japan.
Article Synopsis
- * The research included 115 T1DM patients and assessed their dietary habits, abdominal symptoms, and serum anti-tissue transglutaminase (TTG) antibody levels to diagnose CD.
- * Results showed that 50.4% of patients reported abdominal symptoms, but none had elevated TTG levels, leading to the conclusion that the prevalence of CD in Japanese patients with T1DM is 0%, indicating a lower occurrence than seen in other countries.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!